Reuters logo
BRIEF-Nabriva therapeutics announces positive topline results
September 18, 2017 / 11:15 AM / 3 months ago

BRIEF-Nabriva therapeutics announces positive topline results

Sept 18 (Reuters) - Nabriva Therapeutics PLC

* Nabriva Therapeutics announces positive topline results from global, phase 3 clinical trial evaluating IV and oral lefamulin for the treatment of community-acquired bacterial pneumonia

* Nabriva Therapeutics PLC - ‍lefamulin met all primary FDA and EMA endpoints with a favorable tolerability profile​

* Nabriva - ‍in leap 1 trial, similar rate of treatment-emergent adverse events observed in lefamulin arm and moxifloxacin with or without linezolid arm​

* Nabriva Therapeutics PLC - ‍company expects to complete enrollment in Q4 of 2017, and to have topline data available in spring of 2018 for leap 2​

* Nabriva Therapeutics PLC - ‍death occurred with similar frequency in both lefamulin arm and moxifloxacin with or without linezolid arm​

* Nabriva Therapeutics PLC - ‍6 patients died in lefamulin arm and 5 patients died in moxifloxacin with or without linezolid arm​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below